Alexandra Gerlach, Content Producer

The trial showed that adding pelabresib to ruxolitinib improved outcomes in myelofibrosis with manageable adverse effects.

CAV-1 is a key protein in lipid rafts that helps control cellular processes such as growth, survival, and migration.

Siremadlin is a novel, investigational, second-generation antagonist that binds to MDM2.

The predictive tool may reveal the mechanisms underlying treatment resistance in patients with HER+ breast cancer.

Real-time profiling of T-cell activation states in non-CAR T-cells may help guide treatment decisions.

Pharmacists performed weekly toxicity and tumor lysis syndrome monitoring.

John Ostrominski, MD shares insights into the safety and efficacy of finerenone, based on data from the FINEARTS-HF trial.

The CDC reports 483 total cases across 20 states as of March 28, 2025.

Sarah Spinler, PharmD, FCCP, FAHA, FASHP, AACC, discussed management of atrial fibrillation in patients with cancer.

Anna Sophie Mueller, MD discusses how imaging could advance risk identification in cardiovascular care.

Marc Humbert, MD, PhD, shared data that were presented at the ACC 2025 Scientific Sessions.

Jawad Butt, MD, offers insight into his analysis of the FINEARTS-HF trial.

John Buse, MD, PhD discusses the expanding role of GLP-1 receptor agonists in treatment of cardiovascular conditions.

Christian Ruff, MD, highlights abelacimab’s potential to significantly reduce bleeding in patients with high-risk atrial fibrillation.

Marc Bonaca, MD, PHH, FACC discussed semaglutide’s potential benefits for non-diabetic patients with peripheral artery disease.

Colorectal cancer cases are on the rise—here is everything you need to know as an oncology pharmacist.

Aromatase inhibitors were superior to tamoxifen in reducing risk of contralateral breast cancer.

Patients with chronic lymphocytic leukemia (CLL) show weakened T-cell memory responses to COVID-19 vaccination.

The findings provide a deeper understanding of the mechanisms underlying breast cancer progression and treatment resistance.

Adding daratumumab improved minimal residual disease (MRD) negativity rates, leading to superior progression-free survival (PFS).

Patients achieved statistically significant benefits in progression-free survival and overall response rates.

The study aims to address lingering public concerns, but its findings and communication have the potential to impact vaccine confidence and public health efforts.

Patients with central nervous system (CNS) involvement achieved favorable outcomes with chimeric antigen receptor (CAR) T-cell therapy.

Sjögren's disease is one of the most common chronic autoimmune diseases that affects 4 million individuals around the world.

The agent is the only approved therapy designed to address the underlying mechanisms of the disease.

BeeR is a bacterial protein from the family Verrucomicrobiota that influences cell shape and division.

As demand for GLP-1 therapies grows, patients face rising costs and restrictive insurance policies.

The combination was approved for treatment of patients with gastroesophageal junction (GEJ) adenocarcinoma.

Exidavnemab is a novel monoclonal antibody with disease-modifying potential.

Reducing the dose of ibrutinib following adverse events improved tolerability without compromising clinical efficacy in chronic lymphocytic leukemia (CLL).